Cipla Rolls Out Yurpeak Tirzepatide to Expand Access Across India

Cipla Limited has introduced Yurpeak (tirzepatide) in India, a once?weekly injectable therapy aimed at managing obesity and type?2 diabetes mellitus.

After approval by DCGI, the company will market and sell Yurpeak the second brand of tirzepatide in the country that is made by Lilly. This initiative puts Cipla ahead of an expanding treatment market helped by increasing metabolic health issues.

The first dual agonist, which is a GIP and GLP-1 receptor, is tirzepatide. It is authorized as an adjunct to diet and exercise in adult patients with type 2 diabetes, and in the chronic weight loss of obese adults or the overweight with one or more associated conditions. Cipla wants to expand the availability of this therapy with Yurpeak and help more patients who demand more sophisticated therapies.

Also Read: How Pharma Authentication Tech Enhances ROI and Safety

In response to the launch, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said: The launch of Yurpeak is a revolutionary event in the fight against obesity and type 2 diabetes mellitus, which is one of the burdensome chronic conditions in India.

Cipla is getting into this field with the same magnitude of competence and scientific dedication that characterize our leadership in chronic diseases and in respiratory care. We will continue to focus on increasing access to globally benchmarked and future-ready therapies through such partnerships as ours with Lilly, which combine innovation, purpose and scale to provide advanced care to patients wherever they are.

Cipla will distribute tirzepatide as far as possible, both in urban and non-metro areas, by accessing its countrywide network. Yurpeak will be manufactured and supplied by Lilly at the same price as Mounjaro. Patient education will facilitate the rollout process using dosing, self-administration and safe use patient education programs, which will strengthen Cipla to embrace responsible, evidence-based care.